Several Chinese medicines (CMs) have been recommended by the National Health Commission of China (NHCC) for the treatment of coronavirus disease 2019 (COVID-19). (1,2) Also, these CMs have been recommended for different clinical phenotypes. Significant clinical efficacy and safety of NHCC-recommended CMs have recently been reported based on a multicenter, prospective and randomized controlled trial (3) and a retrospective analysis (4) of the CM-treated COVID-19 patients. Nonetheless, concerns have been raised about the lack of understanding of the therapeutic mechanisms and the insufficient attention to the clinical adverse effects of these CMs. (5-7) As part of the efforts for resolving these concerns, investigations have been conducted for probing the mechanisms, particularly the targets and regulated networks, of the CMs for the treatment of COVID-19. (8-14) These investigations have revealed the possible targets of the NHCC-recommended CMs in the modulation of the COVID-19 pathological processes, particularly the inhibition of COVID-19 replications, (9-13) the modulation of hyperinflammations (9,10,15) and the reduction of tissue
Chin J Integr Med 2022 Jul;28(7):627-635

Our study suggests that the East (CM) meets West (conventional medicine) in common therapeutic mechanisms against COVID-19 pathophysiology, particularly by common mechanisms with the conventional medicines. We therefore applied target-evaluation rules to analyze the experimentally-determined potent targets of 11 NHCC-recommended CMs (Appendix 1) for searching the common targets with respect to the 3 sets of targets of conventional medicines. The first set contains the targets of COVID-19 pathophysiology discovered by the COVID-19 target discovery studies. The second and third sets are the targets of the approved or clinical trial drugs for the treatment of the major COVID-19 complications and comorbidities, respectively. The common targets were selected based on the match in both target protein and activity type (inhibition/antagonism or activation/agonism).

METHODS

CMs and Target Data Collection

NHCC-recommended CMs for the treatment of COVID-19 were collected from the 5th and 7th editions of the NHCC guidelines. The constituent herbs of these CMs and their chemical ingredients were from the Traditional Chinese Medicine Information Database (TCM-ID). The experimentally-determined targets and the activity values of the chemical ingredients of these CMs were from the Natural Product Activity and Species Source Database (NPASS). An activity [half maximal inhibitory concentration (IC50) or inhibition constant (Ki)] cut-off value of \( \leq 1 \mu \text{mol/L} \) was used for selecting the potent targets of these CMs. The reference record
Therapeutic Target Database (TTD) and DrugBank databases by using the names of drugs and target data collection. The pathways of targets are from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The approved and clinical trial drugs against these targets were searched from the TTD and DrugBank databases using the names of the complications and comorbidities. The pathways of targets are from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and additional literature search. Literature was searched for removing the same drug of alternative names and confirming they are clinically used against the respective complications and comorbidities.

CM Target Analysis

The clinically-relevant targets of CMs are modulated by the constituent herbs to produce distinguished potent activities. These herbs belong to certain traditionally-characterized classes. The larger classes are heat clearing and detoxification (50 herbs), qi regulating (41 herbs), cough and asthma (29 herbs), heat clearing and fire purging (23 herbs), divergent wind chill (21 herbs), and divergent wind fever (20 herbs). The clinical effects of each class likely arise from potent activities against more than 1 target distinguished from the targets of other classes. Therefore, the clinically-relevant targets of CMs are expected to be non-ubiquitous targets, i.e., they are the potent targets of limited number of herbs. Based on the numbers of herbs in the larger classes, we tentatively set a non-ubiquitous target threshold of no more than 30 herbs. Variation of the cut-off values from 25 and 35 herbs only led to small variations of the results. The non-ubiquitous potent targets of CMs were compared to the targets of the 2 COVID-19 target discovery studies, and the targets of the approved or clinical trial drugs for the treatment of the major COVID-19 complications and comorbidities. For the matched targets, the activity type of each CM ingredient and drug were further compared, and the targets of matched activity types were recorded as the targets of the common targets of CMs and drugs. The network graphs of the identified common targets were constructed by using Cytoscape (version 3.7.2, supported by the U.S. National Institute of General Medical Sciences).

RESULTS

Targets of NHCC-Recommended CMs for Treatment of COVID-19

Of the 11 NHCC-recommended CMs (Appendix 1), 5 CMs are for the medical observation period before diagnosis, and 6 CMs for the clinical treatment period. In particular, 3 established CMs [Lianhua Qingwen Capsules, Jinhua Qinggan Granules (金花清感颗粒), and Xuebijing Injection (血必净注射液)] and 3 recipes [Qingfei Paidu Decoction (清肺排毒汤), Xuanfei Baidu Formula (宣肺败毒方), and Huashi Baidu Formula (宣肺败毒方)] have shown clinical efficacies in COVID-19 patients. Appendix 2 lists the constituent herbs, chemical ingredients, the experimentally-determined potent targets and activity values of these 11 CMs. Appendix 3 provides the comparison of the potent targets and activity types of the CMs with the 3 sets of targets of conventional medicines. Several common targets were identified. The graphic view of these targets and the matched CMs and drugs are shown in Figure 1.

Figure 1. Graphic View for Common Targets of NHCC-Recommended CMs with Respect to 3 Sets of Targets of Conventional Medicines

Notes: The targets of conventional medicines include the targets of the recent target discovery studies against COVID-19 pathological processes, and the targets of the approved or clinical trial drugs for the treatment of COVID-19 complications and comorbidities, respectively. Only the drugs that match the activity type of the corresponding CMs are shown, the same below. HXZQ: Huoxiang Zhengqi Capsules; LHQM: Lianhua Qingwen Capsules; JHQQ: Jinhua Qinggan Granules; SFJD: Shufeng Jiedu Capsules; FFTS: Fangfeng Tongsheng Pills; XBJ: Xuebijing Injection; SHX: Suhexiang Pills; AGNH: Angong Niuhuang Pills; the same below.
Common Targets of CMs and Conventional Drugs against COVID-19 Pathophysiology

The viral pathological processes are promoted by the virus-host protein interactions and virus-induced host protein upregulations, which have been the focuses of the COVID-19 target discovery studies,(16,17) We identified 5 common targets of 9 NHCC-recommended CMs with respect to the targets revealed by these target discovery studies,(16,17) each CM modulating at least 1 inflammation regulatory target (Appendix 4). These 5 common targets are all inhibited by the matched CMs and drugs, and 4 of them are the targets of approved or clinical trial drugs with drug repurposing potential. As shown in Figure 2, 1 identified target MIF is a common target of 7 CMs [Fangfeng Tongsheng Pills (防风通圣丸), Suhexiang Pills (苏合香丸), Qingfei Paidu Decoction, Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Xuanfei Baidu Formula, and Huashi Baidu Formula]. This target is in the top-3 ranked protein clusters of the targets revealed by the proteomics-based COVID-19 target discovery study.(17) MIF is a critical mediator of macrophage inflammatory cytokine production and innate immune responses,(39) and is targeted by a phase 2 (imalumab) and a preclinical (COR100140) inhibitor drug against cancers and inflammation, respectively.

Figure 2. Common Targets of NHCC-Recommended CMs with Respect to Two Recent COVID-19 Target Discovery Studies

Another identified target DNMT1 is a common target of 2 CMs [Fangfeng Tongsheng Pills and Angong Niuhuang Pills (安宫牛黄丸)], which interacts with COVID-19 ORF8 protein.(16) DNMT1 regulates macrophage inflammation(36) and T-cell development,(37) and is targeted by 5 inhibitor drugs in cancer clinical trials (guadecitabine, antroquinonol, palifosfamide, RX-3117, and oral azacitidine). The third common target CDK1 of 3 CMs (Xuanfei Baidu Formula, Huashi Baidu Formula, and Xuebijing Injection) has been discovered by the proteomics-based COVID-19 target discovery study.(17) It reportedly regulates replications of certain viruses,(38) and is targeted by 6 inhibitor drugs in clinical trials (Ro 31-7453, AG-024322, PHA-793887, P276-00, R-roscovitine, RGB-286638) and 2 preclinical drugs (ON-01135, L-751250) against cancers and obesity.

The fourth target POLA1 of 1 CM (Qingfei Paidu Decoction) has been discovered by the interactomics-based COVID-19 target discovery study.(16) It is a critical regulator of type 1 interferon inflammatory response,(39) and is targeted by an inhibitor drug (HO-221) in clinical trial against viral infections. The fifth target TUBB3 of 4 CMs (Fangfeng Tongsheng Pills, Angong Niuhuang Pills, Qingfei Paidu Decoction, and Jinhua Qinggan Granules) has also been discovered by the interactomics-based COVID-19 target discovery study.(16) TUBB3 is a tubulin that interacts with viral protein to facilitate viral transcription,(40,41) These common targets indicate the common mechanisms of CMs and conventional medicines in targeting macrophage-mediated inflammation and viral replication processes in COVID-19.

Interestingly, 7 of the 9 identified NHCC-recommended CMs for the treatment of particular phenotypes appear to target distinguished sets of common targets that are different from the CMs for the other phenotypes. As shown in Appendixes 1 and 4, there are 3 CMs (Lianhua Qingwen Capsules, Jinhua Qinggan Granules, and Fangfeng Tongsheng Pills) for the treatment of the phenotype of fatigue with fever in the medical observation period, which either target MIF or co-target MIF and TUBB3 or simultaneously target MIF, TUBB3 and DNMT1. There is 1 CM (Xuanfei Baidu Formula) for the treatment of 2 phenotypes of mild and general cases in the clinical treatment period, which targets CDK1 and MIF. There are 3 CMs (Huashi Baidu Formula, Qingfei Paidu Decoction, and Xuebijing Injection) for the treatment of the phenotype of severe cases in the clinical treatment period (Xuebijing Injection is also for critical cases), the first two of which either co-target POLA1 and MIF or simultaneously target POLA1, MIF, and TUBB3. There are 3 CMs (Angong Niuhuang Pills, Suhexiang Pills, and Xuebijing Injection) for the treatment of the phenotype of critical cases in the clinical treatment period (Xuebijing Injection is also for severe cases), the first one of which targets DNMT1 and TUBB3. Nonetheless, there are 2 CMs with unclear phenotype-
target association. Specifically, Suhexiang Pills for the critical cases and Xuebijing Injection for the critical and severe cases in the clinical treatment period are each with 1 common target (CDK1 and MIF) only, which are not distinguished from the targets of the CMs for the other phenotypes. One possible reason is that not all targets of these 2 CMs have been revealed by the COVID-19 target discovery studies\(^{(16,17)}\) because of limited patient populations in the investigations.

### Common Modulated Proteins of CMs and Conventional Drugs Against Major COVID-19 Complications

For the 5 major COVID-19 complications,\(^{(21,22)}\) we identified 6 potent modulated proteins of 8 NHCC-recommended CMs in common with the targets of drugs against 2 major COVID-19 complications (pain and headache (Appendix 5). Specifically, 1 CM modulates a target of pain and a target of headache, 5 CMs modulate a target of pain, and 2 CMs modulate a target of headache (Figure 3). ADRA2A is agonized by 4 CMs (Suhexiang Pills, Angong Niuhuang Pills, Xuanfei Baidu Formula, and Huashi Baidu Formula) and a phase 2 drug against pain (medetomidine). ADRA2C is agonized by 2 CMs (Suhexiang Pills and Angong Niuhuang Pills) and a phase 2 drug (fadolmidine) against pain. ADRA2 subtypes regulate neuroactive ligand-receptor interaction and cyclic guanosine monophosphate-protein kinase G (cGMP-PKG) signaling. Their agonists produce analgesia, anxiolysis, sedation, and sympatholysis effects for the treatment of chronic pains.\(^{(42)}\) TRPV1 is inhibited by 2 CMs [Huoxiang Zhengqi Capsules (藿香正气胶囊) and Qingfei Paidu Decoction] and 8 clinical trial drugs against pain (DWP-05195, GRC-15300, MR-1817, PF-3864086, PHE-377, SAR-115740, ABT-102, and JNJ-39439335). TRPV1 is a multimodal sensor of noxious stimuli that triggers counteractive measures against pain and injury, and TRPV1 activation leads to chronic inflammatory pain and peripheral neuropathy, making TRPV1 a promising target against pain.\(^{(43)}\)

There are 3 common modulated proteins against headache. Two proteins are 5-hydroxytryptamine (5-HT) receptor subtypes HTR1B/ HTR1D agonized by 3 CMs (Fangfeng Tongsheng Pills, Lianhua Qingwen Capsules, and Huashi Baidu Formula) and 4 agonist drugs (naratriptan, almogran, rizatriptan, and sumatriptan) against migraine. Another protein HTR1F is agonized by 1 CM (Huashi Baidu Formula) and 1 agonist drug (lasmiditan) in clinical trial against migraine. The 5-HT receptor subtypes HTR1B/ HTR1D and HTR1F mediate neuroactive ligand-receptor interactions and subsequently with migraine pathophysiology.\(^{(44)}\) The agonists of these receptor subtypes have been developed as subtype-selective drugs against migraine.\(^{(45)}\)

### Common Modulated Proteins of CMs and Conventional Drugs Against Major COVID-19 Comorbidities

Of the 3 major COVID-19 comorbidities reported in the literatures,\(^{(23-26)}\) we identified 5 potent modulated proteins of 11 NHCC-recommended CMs in common with the targets of drugs against 3 major COVID-19 comorbidities (hypertension, obesity, and diabetes, Appendix 6). Specifically, 1 CM (Jinhua Qinggan Granules) modulates a hypertension and a diabetes target, 1 CM (Suhexiang Pills) modulates a hypertension and an obesity target, 3 CMs (Fangfeng Tongsheng Pills, Lianhua Qingwen Capsules, and Huashi Baidu Formula) modulate an obesity and a diabetes target, 1 CM (Angong Niuhuang Pills) modulates a hypertension target, and 5 CMs (Xuanfei Baidu Formula, Xuebijing Injection, Huoxiang Zhengqi Capsules, Qingfei Paidu Decoction, and Shufeng Jiedu Capsules) modulate a diabetes target, respectively (Figure 4). ADRA2C is agonized by 2 CMs (Suhexiang Pills and Angong Niuhuang Pills) and 1 agonist drug (rilmenidine) approved for hypertension. ADRA2 receptor agonists have been used for hypertension and patients withdrawing from long-term abuse of drugs or alcohol.\(^{(42)}\) At lower doses, these agonists block the sympathetic arm of the autonomic nervous system mediated by the α2A-adrenergic receptor subtype, thereby producing the antihypertensive effects.\(^{(42)}\)
The second modulated protein PDE5A is inhibited by 1 CM (Jinhua Qinggan Granules) and 1 inhibitor drug (dipyridamole) approved for hypertension. PDE5 subtypes regulate cGMP-PKG signaling in pulmonary vascular homeostasis, and PDE5 inhibitors have been used for pulmonary arterial hypertension.\(^{(46)}\)

There is 1 common modulated protein against obesity, which is HTR2C agonized by 4 CMs (Fangfeng Tongsheng Pills, Suhexiang Pills, Lianhua Qingwen Capsules, and Huashi Baidu Formula) and 2 agonist drugs (lorcaserin, ATHX-105) approved or in phase 2 trial against obesity. Partly due to the regulation of the brain serotonin (5-HT) system, HTR2C agonists reduce feeding and body weight to elicit anti-obesity effects.\(^{(47)}\) There are 2 common modulated proteins against diabetes. One protein FFAR1 is agonized by 3 CMs (Xuanfei Baidu Formula, Huashi Baidu Formula, and Xuebijing Injection) and 2 agonist drugs (Fasiglifam, JTT-851). FFAR subtypes regulate energy metabolism in adipose tissue, and are targeted against metabolic disorders such as diabetes.\(^{(48)}\) The second modulated protein HSD11B2 is inhibited by 8 CMs [Huoxiang Zhengqi Capsules, Fangfeng Tongsheng Pills, Qingfei Paidu Decoction, Lianhua Qingwen Capsules, Jinhua Qinggan Granules, Shufeng Jiedu Capsules, Qinggan Granules, Shufeng Jiedu Capsules, and 1 inhibitor drug (RG-7234) in clinical trial against diabetes. HSD11B2 regulates diabetes by activating cortisone to cortisol hormone biosynthesis, leading to hypercortisolism associated with metabolic syndromes.\(^{(49)}\)

**DISCUSSION**

The common targets of the NHCC-recommended CMs and the COVID-19 target discovery studies can be divided into 2 groups. The first group contains cytokines and regulators, which include a cytokine (MIF targeted by 7 CMs) for inflammatory responses,\(^{(36)}\) a DNA methyltransferase (DNMT1 targeted by 2 CMs) for epigenetic regulation of macrophage-mediated inflammation,\(^{(50)}\) and a DNA polymerase (POLA1 targeted by 1 CM) for modulating the activation of certain cytokines.\(^{(39)}\) The second group contains viral replication regulators, which include a cell-cycle regulator (CDK1 targeted by 3 CMs) for facilitating viral replications,\(^{(38)}\) and a tubulin (TUBB3 targeted by 4 CMs) for promoting the viral genome transcription.\(^{(40,41)}\)

Experimental studies have confirmed that CMs such as Lianhua Qingwen Capsules repress COVID-19 partly by regulating proinflammatory cytokines and viral replications.\(^{(8)}\) Cytokine regulation is a key antiinflammatory mechanism of CM herbs.\(^{(51)}\) Our study is consistent with these findings.
regulated processes are manifested in COVID-19, but are not yet fully covered by the proteomics and interactomics based target discovery studies.

Secondly, the focus of the common targets neglects network regulatory effects of the CMs. *In silico* and experimental study of Qingfei Paidu Decoction in COVID-19 infected cells has found a network of targets enriched in the regulation of several process, including the interaction, catalysis and activity regulation of proteins in subcellular organelles and cell membrane. 

A study of Qingfei Paidu Decoction has shown that its major chemical ingredients target distinguished nodes of the target-pathway-disease networks associated with the regulation of antiviral, antiinflammatory activity and metabolic programming. Network pharmacology study of CMs against COVID-19 has also indicated that CMs regulate IL-17 and TNF pathway. The coordinated modulations of CMs against these pathways are inadequately covered by the proteomics and interactomics based studies.

Thirdly, the focus on the potent targets neglects the synergistic actions of CMs. Analysis of the 124 experimentally-determined synergistic combinations of natural products has revealed that it is possible to assemble the sub-potent natural products into highly-potent combinations albet at low probabilities. The CMs for COVID-19 therapeutics likely involve highly-potent synergistic combinations of the chemical ingredients. Indeed, several studies have suggested that the potency-enhancing synergistic effects of the CMs are important parts of the mechanisms against COVID-19 as well as other diseases. These synergistic effects may provide useful clues for the development of the COVID-19 cocktail therapies in conventional medicines. Hence, there is a need for more comprehensive investigations of the synergistic actions in CMs.

In conclusion, NHCC-recommended CMs have exhibited significant clinical effects, partly arise from the mechanisms in common with conventional medicines. Our investigation here showed that individual NHCC-recommended CMs not only modulate the COVID-19 pathological processes, but also modulate the major COVID-19 complications and comorbidities, partly in common mechanisms with the conventional medicines. This conforms to the CM formulation principle of co-targeting the pathological factors and maladjustments. Moreover, CMs produce beneficiary effects by synergistic activities against relevant biological networks. In some cases, chemical ingredients of sub-potent activities can be synergistically combined into potent combinations. Therefore, further investigations of various potent and clinically-active targets of CMs from the perspectives of network regulations and synergistic activities may enable deeper understanding of the mechanisms of the NHCC-recommended CMs against COVID-19 pathophysiology, complications and comorbidities.

**Conflict of Interest**

The authors declare no competing interests.

**Author Contributions**

Chen YZ conceived and designed this research. Wang SS collected and analyzed the data. Zeng X contributed analytic tools. Wang YL and ZD provided constructive suggestions. Zhao YF reviewed the manuscript. Wang SS and Chen YZ wrote the paper.

**Electronic Supplementary Material:** Supplementary material (Appendices 1–6) is available in the online version of this article at https://doi.org/10.1007/s11655-022-3573-0.

**REFERENCES**

1. National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J 2020;133:1087-1095.
2. Ho LTF, Chan KKH, Chung VCH, Leung TH. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. Eur J Integr Med 2020;36:101116.
3. Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2020;85:153242.
4. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med 2020;15:34.
5. Redeploying plant defences. Nat Plants 2020;6:177.
6. Gray PE, Belessis Y. The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good. Pharmacol Res 2020;156:104776.
7. Yang Y. Use of herbal drugs to treat COVID-19 should be with caution. Lancet 2020;395:1689-1690.
8. Li RF, Hou YL, Huang JC, Pan WQ, Ma QH, Shi YX, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory
activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761.
9. Yang R, Liu H, Bai C, Wang Y, Zhang X, Guo R, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res 2020;157:104820.
10. Kageyama Y, Aida K, Kawauchi K, Morimoto M, Ebisui T, Akiyama T, et al. Jinhuang Qinggan Granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL-6 and IFN-γ: an open-label, single-arm pilot study. World Acad Sci J 2022;4:2.
11. Huang YF, Bai C, He F, Xie Y, Zhou H. Review on the potential action mechanisms of Chinese medicines in treating coronavirus disease 2019 (COVID-19). Pharmacol Res 2020;158:104939.
12. Wang SS, Zeng X, Wang YL, Zhao YF, Chen WP, Chen YZ. East meets West in COVID-19 therapeutics. Pharmacol Res 2020;159:105008.
13. Gao LQ, Xu J, Chen SD. In silico screening of potential Chinese herbal medicine against COVID-19 by targeting SARS-CoV-2 3CLpro and angiotensin converting enzyme II using molecular docking. Chin J Integr Med 2020;26:527-532.
14. Yu S, Wang J, Shen H. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19. Ann Palliat Med 2020;9:437-446.
15. Wang YL, Zeng X, Zhao YF, Chen WP, Chen YZ. The pros and cons of traditional Chinese medicines in the treatment of COVID-19. Pharmacol Res 2020;157:104873.
16. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020;583:459-468.
17. Bojkova D, Kliann K, Koch B, Widera M, Krause D, Ciesek S, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature 2020;583:469-472.
18. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci 2005;26:558-563.
19. Wang L, Zhang RM, Liu GY, Wei BL, Wang Y, Cai HY, et al. Chinese herbs in treatment of influenza: a randomized, double-blind, placebo-controlled trial. Respir Med 2010;104:1362-1369.
20. Wong W, Lam CLK, Bian XZ, Zhang ZJ, Ng ST, Tung S. Morbidity pattern of traditional Chinese medicine primary care in the Hong Kong population. Sci Rep 2017;7:7513.
21. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683-690.
22. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth 2020;125:436-440.
23. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Resp Med 2020;8:e21.
24. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546-550.
25. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.
26. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020;323:2052-2059.
27. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess deaths from COVID-19 and other causes, March-April 2020. JAMA 2020;324:510-513.
28. Chen X, Zhou H, Liu YB, Wang JF, Li H, Ung CY, et al. Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Br J Pharmacol 2006;149:1092-1103.
29. Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, et al. NPASS: natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res 2018;46:D1217-D1222.
30. Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res 2020;48:D1031-D1041.
31. Wishart DS, Feunang YD, G solitary E, Li WJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074-D1082.
32. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017;45:D353-D361.
33. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504.
34. The State Council Information Office. SCIO briefing on TCM’s important role and a list of effective drugs in COVID-19 prevention and control. Accessed March 25, 2020. Available at http://english.scio.gov.cn/pressroom/2020-03/25/content_75858152_0.htm.
35. Das R, Koo MS, Kim BH, Jacob ST, Subbian S, Yao J, et al. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium
tuberculosis. Proc Natl Acad Sci U S A 2013;110:E2997-E3006.
36. Tang RZ, Zhu JJ, Yang FF, Zhang YP, Xie SA, Liu YF, et al. DNA methyltransferase 1 and Kruppel-like factor 4 axis regulates macrophage inflammation and atherosclerosis. J Mol Cell Cardiol 2019;128:11-24.
37. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, et al. A critical role for DNMT1 and DNA methylation in T cell development, function, and survival. Immunity 2001;15:763-774.
38. Hertel L, Chou S, Mocarski ES. Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog 2007;3:e6.
39. Starokadomskyy P, Gemelli T, Rios JJ, Xing C, Wang RC, Li H, et al. DNA polymerase-alpha regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol 2016;17:495-504.
40. Ogino T, Iwama M, Ohsawa Y, Mizumoto K. Interaction of cellular tubulin with Sendai virus M protein regulates transcription of viral genome. Biochem Biophys Res Commun 2003;311:283-293.
41. Naghavi MH, Walsh D. Microtubule regulation and function during virus infection. J Virol 2017;91:e00538-17.
42. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 2000;93:1345-1349.
43. Brito R, Sheth S, Mukherjea D, Rybak LP, Ramkumar V. TRPV1: a potential drug target for treating various diseases. Cells 2014;3:517-545.
44. Sicuteri F. Headache as possible expression of deficiency of brain 5-hydroxytryptamine (central denervation supersensitivity). Headache 1972;12:69-72.
45. Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics 2018;15:291-303.
46. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008;32:198-209.
47. Bickerdike MJ. 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 2003;3:885-897.
48. Ichimura A, Hasegawa S, Kasubuchi M, Kimura I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol 2014;5:236.
49. Pereira CD, Azevedo I, Monteiro R, Martins MJ. 11Beta-hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:869-881.
50. Chen S, Yang J, Wei Y, Wei X. Epigenetic regulation of macrophages: from homeostasis maintenance to host defense. Cell Mol Immunol 2020;17:36-49.
51. Pan MH, Chou YS, Tsai ML, Ho CT. Anti-inflammatory activity of traditional Chinese medicinal herbs. J Tradit Complement Med 2011;1:8-24.
52. Tong T, Wu YQ, Ni WJ, Shen AZ, Liu S. The potential insights of traditional Chinese medicine on treatment of COVID-19. Chin Med 2020;15:51.
53. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol 2020;20:389-391.
54. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489-500.
55. Chen J, Wang YK, Gao Y, Hu LS, Yang JW, Wang JR, et al. Protection against COVID-19 injury by Qingfei Paidu Decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother 2020;129:110281.
56. Pan HD, Yao XJ, Wang WY, Lau HY, Liu L. Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients. Pharmacol Res 2020;159:105043.
57. Qin C, Tan KL, Zhang CL, Tan CY, Chen YZ, Jiang YY. What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? PLoS One 2012;7:e49969.
58. Ren X, Shao XX, Li XX, Jia XH, Song T, Zhou WY, et al. Identifying potential treatments of COVID-19 from traditional Chinese medicine (TCM) by using a data-driven approach. J Ethnopharmacol 2020;258:112932.
59. Luo L, Jiang J, Wang C, Fitzgerald M, Hu W, Zhou Y, et al. Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharmaceutica Sinica B 2020;10:1192-1204.
60. Liu J, Liu J, Shen F, Qin Z, Jiang M, Zhu J, et al. Systems pharmacology analysis of synergy of TCM: an example using saffron formula. Sci Rep 2018;8:380.
61. Zhang A, Sun H, Wang X. Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine. Phytother Res 2014;28:526-533.
62. Su X, Yao Z, Li S, Sun H. Synergism of Chinese herbal medicine: illustrated by Danshen Compound. Evid Based Complement Alternat Med 2016;2016:7279361.
63. Ma XH, Zheng CJ, Han LY, Xie B, Jia J, Cao ZW, et al. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discov Today 2009;14:579-588.